Review



cpass sars-cov-2 neutralization antibody detection kit  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation cpass sars-cov-2 neutralization antibody detection kit
    Cpass Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cpass sars-cov-2 neutralization antibody detection kit/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    cpass sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-04
    90/100 stars

    Images



    Similar Products

    anti sars cov 2 antibody igg4 titer serologic assay kit  (ACROBiosystems)
    95
    ACROBiosystems anti sars cov 2 antibody igg4 titer serologic assay kit
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Anti Sars Cov 2 Antibody Igg4 Titer Serologic Assay Kit, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2 antibody igg4 titer serologic assay kit/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    anti sars cov 2 antibody igg4 titer serologic assay kit - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    anti sars cov 2 neutralising antibody titre serologic assay kit  (ACROBiosystems)
    95
    ACROBiosystems anti sars cov 2 neutralising antibody titre serologic assay kit
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Anti Sars Cov 2 Neutralising Antibody Titre Serologic Assay Kit, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2 neutralising antibody titre serologic assay kit/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    anti sars cov 2 neutralising antibody titre serologic assay kit - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    antibody titer serologic assay kit  (ACROBiosystems)
    95
    ACROBiosystems antibody titer serologic assay kit
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Antibody Titer Serologic Assay Kit, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody titer serologic assay kit/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    antibody titer serologic assay kit - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    anti sars cov 2  (ACROBiosystems)
    95
    ACROBiosystems anti sars cov 2
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Anti Sars Cov 2, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    anti sars cov 2 - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    anti sars cov 2 neutralizing antibody titer serological assay kit  (ACROBiosystems)
    95
    ACROBiosystems anti sars cov 2 neutralizing antibody titer serological assay kit
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Anti Sars Cov 2 Neutralizing Antibody Titer Serological Assay Kit, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2 neutralizing antibody titer serological assay kit/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    anti sars cov 2 neutralizing antibody titer serological assay kit - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    anti sars cov 2 neutralizing antibody titer assay  (ACROBiosystems)
    95
    ACROBiosystems anti sars cov 2 neutralizing antibody titer assay
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Anti Sars Cov 2 Neutralizing Antibody Titer Assay, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sars cov 2 neutralizing antibody titer assay/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    anti sars cov 2 neutralizing antibody titer assay - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    cpass sars-cov-2 neutralization antibody detection kit  (GenScript corporation)
    90
    GenScript corporation cpass sars-cov-2 neutralization antibody detection kit
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Cpass Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cpass sars-cov-2 neutralization antibody detection kit/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    cpass sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cpass neutralization antibody detection kit  (GenScript corporation)
    90
    GenScript corporation cpass neutralization antibody detection kit
    Distribution of <t>IgG-RBD-S</t> antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.
    Cpass Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cpass neutralization antibody detection kit/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    cpass neutralization antibody detection kit - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Distribution of IgG-RBD-S antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Distribution of IgG-RBD-S antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques: Infection

    Level of IgG-RBD-S antibodies based on the number of doses. Oncologic patients were divided according to the number of doses, including the Comirnaty Omicron XBB 1.5 they were receiving (4 TH - Onc and 5 TH - Onc, the most represented groups). A control group receiving the 5 TH dose is also reported. IgG-RBD-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The p value of Kruskal-Wallis test for unpaired data at a specific time point is reported.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Level of IgG-RBD-S antibodies based on the number of doses. Oncologic patients were divided according to the number of doses, including the Comirnaty Omicron XBB 1.5 they were receiving (4 TH - Onc and 5 TH - Onc, the most represented groups). A control group receiving the 5 TH dose is also reported. IgG-RBD-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The p value of Kruskal-Wallis test for unpaired data at a specific time point is reported.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques: Control

    Distribution of IgG-RBD-S antibodies among IgM-S(+) and IgM-S(-) patients before (T1) and after (T2) the dose administration among the 48 oncologic patients. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots. The p value of Mann-Whitney U test for unpaired data at a specific time point is reported.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Distribution of IgG-RBD-S antibodies among IgM-S(+) and IgM-S(-) patients before (T1) and after (T2) the dose administration among the 48 oncologic patients. Patients with positive IgG-N (thus indicating a previous infection) are reported as red dots, while patients with negative IgG-N are reported as blue dots. The p value of Mann-Whitney U test for unpaired data at a specific time point is reported.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques: Infection, MANN-WHITNEY

    Distribution of IgG4-S antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Distribution of IgG4-S antibodies before (T1) and after (T2) the dose administration among the 48 oncologic patients. Wilcoxon signed-rank test was applied to assess differences within groups for paired data at different time points.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques:

    Level of IgG4-S antibodies based on the number of doses. Oncologic patients were divided according to the number of doses, including the Comirnaty Omicron XBB 1.5 they were receiving (4 TH - Onc and 5 TH - Onc, the most represented groups). IgG4-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The p value of Mann-Whitney U test for unpaired data at a specific time point is reported.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Level of IgG4-S antibodies based on the number of doses. Oncologic patients were divided according to the number of doses, including the Comirnaty Omicron XBB 1.5 they were receiving (4 TH - Onc and 5 TH - Onc, the most represented groups). IgG4-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The p value of Mann-Whitney U test for unpaired data at a specific time point is reported.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques: MANN-WHITNEY

    Comparison of IgG4-S antibodies between oncologic patients and a control group. Oncologic patients receiving the 5 TH dose were compared with a control group at the same number of doses. IgG4-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The p value of Mann-Whitney U test for unpaired data at a specific time point is reported.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Comparison of IgG4-S antibodies between oncologic patients and a control group. Oncologic patients receiving the 5 TH dose were compared with a control group at the same number of doses. IgG4-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The p value of Mann-Whitney U test for unpaired data at a specific time point is reported.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques: Comparison, Control, MANN-WHITNEY

    Level of IgG-RBD-S antibodies based on the number of doses. The levels observed in the present study for patients receiving the Comirnaty Omicron XBB 1.5 as the 4 TH (4 TH - Onc) or the 5 TH (5 TH - Onc) were compared with data obtained in our previous study on a different cohort of 150 solid tumor patients analyzed before and after the third dose of the Comirnaty Wuhan original vaccine (3 RD - Onc) . A control group receiving the 5 TH dose is also reported. IgG-RBD-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The booster effect based on the antibody level at T1 is reported in panel C (T2-T1). The p value of Kruskal-Wallis test for unpaired data at a specific time point is reported.

    Journal: Frontiers in Immunology

    Article Title: Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients

    doi: 10.3389/fimmu.2025.1699177

    Figure Lengend Snippet: Level of IgG-RBD-S antibodies based on the number of doses. The levels observed in the present study for patients receiving the Comirnaty Omicron XBB 1.5 as the 4 TH (4 TH - Onc) or the 5 TH (5 TH - Onc) were compared with data obtained in our previous study on a different cohort of 150 solid tumor patients analyzed before and after the third dose of the Comirnaty Wuhan original vaccine (3 RD - Onc) . A control group receiving the 5 TH dose is also reported. IgG-RBD-S antibodies levels are shown before (T1, panel A) and after (T2, panel B) the dose administration for the same groups. The booster effect based on the antibody level at T1 is reported in panel C (T2-T1). The p value of Kruskal-Wallis test for unpaired data at a specific time point is reported.

    Article Snippet: For IgG-N and IgM-S, the results were reported as assay index (S/C) with a positive cut-off ≥1.4 for IgG-N and ≥1 for IgM-S. IgG4-S serum levels were analyzed by standard ELISA method, using the Anti-SARS-CoV-2 antibody IgG4 Titer serologic Assay Kit (Acro Biosystem, Delaware, USA), following the manufacturer’s instructions.

    Techniques: Control